4D Molecular Therapeutics (FDMT) Operating Margin (2020 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed Operating Margin for 6 consecutive years, with 67983.33% as the latest value for Q3 2025.
- On a quarterly basis, Operating Margin rose 163641667.0% to 67983.33% in Q3 2025 year-over-year; TTM through Sep 2025 was 191982.5%, a 79845868.0% increase, with the full-year FY2024 number at 507678.38%, down 50713373.0% from a year prior.
- Operating Margin was 67983.33% for Q3 2025 at 4D Molecular Therapeutics, up from 396373.33% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 192900.0% in Q4 2023 to a low of 5611700.0% in Q4 2024.
- A 5-year average of 475592.52% and a median of 13446.03% in 2023 define the central range for Operating Margin.
- Peak YoY movement for Operating Margin: crashed -580460000bps in 2024, then soared 163641667bps in 2025.
- 4D Molecular Therapeutics' Operating Margin stood at 26917.39% in 2021, then surged by 91bps to 2301.28% in 2022, then skyrocketed by 8482bps to 192900.0% in 2023, then plummeted by -3009bps to 5611700.0% in 2024, then surged by 99bps to 67983.33% in 2025.
- Per Business Quant, the three most recent readings for FDMT's Operating Margin are 67983.33% (Q3 2025), 396373.33% (Q2 2025), and 383007.14% (Q1 2025).